US FDA's Presubmission Expedited Regulatory Programs Eyed For Streamlining

 
• By Sue Sutter

Agency staff, stakeholders see advantages to bundling requirements for fast-track and RMAT designations into a single, pre-breakthrough therapy pathway, and codifying processes and interactions that take place following award of breakthrough designation; proposal is aimed at reducing current programs' redundancies and maximizing benefit of frequent, early interactions with the FDA.

Confused undecided businessman watches the complicated road
There is interest in streamlining the US FDA's presubmission expedited pathways. • Source: Shutterstock

More from Review Pathways

More from Pathways & Standards